Seres Therapeutics
MCRB
137 hedge funds and large institutions have $538M invested in Seres Therapeutics in 2023 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 59 increasing their positions, 23 reducing their positions, and 22 closing their positions.
203% more call options, than puts
Call options by funds: $12.8M | Put options by funds: $4.23M
157% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 23
64% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 22
11% more funds holding
Funds holding: 123 → 137 (+14)
0.24% more ownership
Funds ownership: 4.15% → 4.39% (+0.24%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less capital invested
Capital invested by funds: $594M → $538M (-$55.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$26.1M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$11.1M |
| 3 |
Millennium Management
New York
|
+$7.35M |
| 4 |
BlackRock
New York
|
+$6.7M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$6.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$28.4M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$21.1M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$4.36M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.65M |
MCRB Hedge Fund Activity: Q2 2023 in Review
137 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q2 2023, worth a combined $538M — down 9.4% from $594M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new MCRB positions and 22 closed out — a net gain of 14 holders — while 59 added to existing stakes and 23 trimmed.
The largest buyer was State Street, adding an estimated $26.1M. The largest seller was Janus Henderson Group, cutting an estimated $28.4M.
- 137 institutional investors held Seres Therapeutics (MCRB) as of Q2 2023, up from 123 in Q1 2023.
- Funds reported $538M of Seres Therapeutics stock for Q2 2023, down 9.4% quarter-over-quarter.
- 36 funds opened new Seres Therapeutics positions in Q2 2023 and 22 closed out, a net change of +14 holders.
- The largest Seres Therapeutics buyer in Q2 2023 was State Street, an estimated $26.1M added.
- The largest Seres Therapeutics seller in Q2 2023 was Janus Henderson Group, an estimated $28.4M sold.
Based on aggregated 13F filings for Q2 2023.